Urological cancers are substantial burden for public health worldwide, due to their considerable incidence, morbidity and mortality. The cornerstone of an effective disease management is an appropriate diagnostic strategy and early detection. Based on the data from the population-based Geneva cancer registry, this article aimed to report epidemiological trends in urological cancers in Geneva from the last 26 years. Furthermore, it underlines the central role of all practitioners in identifying patients at risk and addressing them to the appropriate diagnostic pathway. This article enables us to take a step back from our current clinical practice in order to highlight their challenges and opportunities and find areas of improvement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2024.20.897.2214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis.
Nat Cancer
January 2025
Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.
View Article and Find Full Text PDFEfficacy and Safety of Low Molecular Weight Heparin and Mechanical Thromboprophylaxis in Immediate Implant-based Breast Reconstruction: A Retrospective Comparative Analysis.
In Vivo
December 2024
Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, Geneva, Switzerland;
Background/aim: Low molecular weight heparin (LMWH) is widely employed to prevent postoperative venous thromboembolism (VTE). This study aimed at analyzing LMWH use and evaluating its efficacy and safety in immediate implant-based post-mastectomy breast reconstruction.
Patients And Methods: A monocentric retrospective analysis was conducted on patients who underwent immediate implant-based breast reconstruction (IBR) from January 2021 to December 2023.
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Ann Rheum Dis
December 2024
Department of Rheumatology, Centre National de Référence des Maladies Auto-Immunes Rares, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.
Objectives: To perform a systematic literature review to inform a Task Force formulating EULAR points to consider on the initiation of targeted therapies in patients with IA and a history of cancer.
Methods: Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian.
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Ann Rheum Dis
December 2024
Department of Rheumatology, Centre National de Référence des Maladies Auto-Immunes Rares, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice.
Objectives: To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.
Methods: Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC.
Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!